{"id":726710,"date":"2023-01-30T07:06:15","date_gmt":"2023-01-30T12:06:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/evoke-announces-teva-ends-pursuit-of-paragraph-iv-anda-against-gimoti\/"},"modified":"2023-01-30T07:06:15","modified_gmt":"2023-01-30T12:06:15","slug":"evoke-announces-teva-ends-pursuit-of-paragraph-iv-anda-against-gimoti","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/evoke-announces-teva-ends-pursuit-of-paragraph-iv-anda-against-gimoti\/","title":{"rendered":"Evoke Announces Teva Ends Pursuit of Paragraph IV ANDA Against Gimoti"},"content":{"rendered":"<h2>\nStipulation of Dismissal of Claims, Defenses and Counterclaims for Patent Infringement Case Filed<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"left\">SOLANA BEACH, Calif., Jan.  30, 2023  (GLOBE NEWSWIRE) &#8212; Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI<sup>\u00ae<\/sup> (metoclopramide) nasal spray, today announced that a joint stipulation of dismissal has been filed in the GIMOTI<sup>\u00ae<\/sup> patent infringement case (Civil Action No. 1:22-cv-02019) in\u00a0the United States\u00a0District Court for the District of New Jersey. The filing of the stipulation arises from Teva Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc.\u2019s (\u201cTeva\u201d) conversion from a Paragraph IV certification to a Paragraph III certification.\u00a0\u00a0 A paragraph III Abbreviated New Drug Application (ANDA) is not eligible for approval until the last expiration date of current and potential future orange book listed patents for the reference listed drug in conjunction with appropriate FDA review.<\/p>\n<p>In addition, no future ANDA filer will be eligible to receive 180-day generic exclusivity for an ANDA that references GIMOTI<sup>\u00ae<\/sup>. This first-to-file regulatory pathway is typically highly sought after by generic firms.<\/p>\n<p align=\"justify\">\u201cThis case has now ended, and we believe the remarkably favorable outcome reflects the strength of the GIMOTI intellectual property and acknowledges the validity of the GIMOTI patents. It also adds to our resolve in defending our rights, even against larger, well-resourced companies,&#8221; said Dave Gonyer, CEO, Evoke Pharma. &#8220;This dismissal will allow us to focus our efforts on continuing to uphold and enhance our company&#8217;s intellectual property in this important category of healthcare innovation.&#8221;<\/p>\n<p>\n        <strong>About\u00a0Evoke Pharma, Inc.<\/strong><br \/>\n        <br \/>Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in\u00a0the United States\u00a0to treat gastroparesis.<\/p>\n<p>Visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6mjhUhg2R9WIjS0_3VIM3OfYqTjVXFIImbYe637ZPNnjNEtSrurmDkpwIwk1FkaVoM-d6t7c4EapD2orO8zAzNXmtkTBnH6fz239Zf0L35w1OzUEDIgy1DN44-rg2Mq4fnxUHe-q_FVosDLFmCinhlLOFTXUI-AlW2PivFEvOeLSvIy8abb_r3EBWPV5E0INMV92a-ElYE9eF6x58YnN97sKBeeQYmDQ69Wa1kFKfo9u3cdfxVKqWWR9j9ITEAX4Eqjnn6asLrEzNQzQtyfuSvNA4WMS7EQxe_SsugpustgHqGT86HnUwQ6rzmqcdcDqLjg9Jz4U19pPPhG5LYnpQ3EJ_zoU8uNOdSvJWqUleYotdCjaLA7bR4W5k1lycbJuM0_WIqR_qNy27heoG2DPqty48sOmRtINuag4EEI2ctaOcsUZn5BG1sEsnpbRV6otEQS74FoakdZAnfMufIPYwppIKUyHo4YG9eJmUFt9fDkDMQYxFfr9NTo6a7Srf5OV88aE0PuW6rFTLg_4VCGe003Cu_iNdaA7NkVVwxmHucs2jh_L85Zt3n5wBOM2Ii-KlU95UswIVczlxwIyj9o3Hn2_Wgw45Ucwg3o8sdJefsUqa8OvIN1Uw78v6kHqUiEDsfYkRcfOoIV2-yxcqdUnV7Dcumu9yLdCN15V2u2hh6bpj00KgvpcMhyf6vHtwEVTRKqQjpKelyoxxGYAG4XrYrCmGXL0iDRyvJzDFszbhTk=\" rel=\"nofollow noopener\" target=\"_blank\">www.EvokePharma.com<\/a>\u00a0for more information.<\/p>\n<p>Follow GIMOTI on Facebook:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WN_spN1sJP5n-euSyASqk-WHmOarvdVLNDBGFkqkDnGafYniQRNzJWqPDk5NAQ5_ZYlcy3PRZmam_TFLuxB2Q1quudJzWdLC2sYT_6lVpX5x17p-v18udeamQI4UDuWfNPrzc-5V1XGC1AEByFcSZ0FUF4ULSyIRyzva_r6hLB7aqs8FtMnpMZnWmB2wUbnXaED0DoONG4Y9c5ivba_Zps2-R1JKJRcmzbFGMryKgODQAJT5g3ZnU1WAL_IqMIcfcjH1WgdcshgRwzaJd0IYlwphODWkxo3QrsgQHvaTNyarhsTFC1tlexih7vrIut-J_dAD8LexSKeny5D29d_c3yzWboAqJvxaZSAer349A-h4TgEQJVCrvp5h8U_I0sBDx1o3sPAFsIpmnKiB2lfmHBC-jsfl9BpcitdCQKKsa7h3DURkMbSVLlwA7W7UiSlCj8T6KfOkcEc28Lz-L708rpIcmnY7sYtiffpuD1pgRPBJOFoJj9-X2spI-mumBZyM91cQ_T_4ZfLZGczcwUWBUYjCoSyeWTH8-ujYUp6lQGdjsTrazOoe6ueqKmsqi7OBKB6tCnYqi3CcxbZUN2W0mSORqrxZZtTWwbn8WyZJ-CF15DWRENI5iuMkf6BYhdIw5j_lCfR7pL0CRIirQw1iadtUvHx4vG7PcLFuO76ZDh30A6WEO8vgVZ0wJ-AYQY7YwTA8lTgSqFC3pknEGHHyFuEdC_-TvoHHFX5iXPh60xJX_FprQzM-FJ4hCiGd0TYbX-aONudCfZzCko88wmjCiyuyYdlh-jiU02mWAdgc2FMWYTXeDo90MbV88UHbza5aPybyzdw98k6DPgUxZULgH8deNf2g1l-ynJr9mVGo2aXvPHqPxYcmCPpPJ0OsXUPtp7isPd0ihrvmo4DwALaiP-bLMVsfx27RM_QzyQfITj5N3h7xNOItedoERXMqveOjepZ3WlcggYmUuhxbhPUB3LKtHUhnLp4GvprxS-T8n7JpxAiz6WMdT4C1qVdPYSjsgE4jpkMhAISVZUF0fgRHqi7s-3xFzpFV4tzgokHH9_oDhQH3QDRIIC8eWAAk6bkpTXr5TSHK3di8qXo0kl3AsAL0vvUCNiET_o4LzPnasPNWg-13i2gEGQ-C3FP4aMOR1OGeW5H_lEG57TGvC9ZoRE--TEO4JbKbc7dJlq5noOVv2i1F05yu2zKN4PNZtT24JFK5SDwizpJEBRxwwclKiM8eoX8Sp0Yw2E9LNHG2JzNy4ok5TtWQArEK7lonDPWkT5ofs12k1gH5N1XIQk-gMP9U2zrTxgoUNgIjoi-ZbqZjF00JYsjLI1XVCgiLnK0pwR6OEJq2lZXQBTgPTGoetw==\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.facebook.com\/GIMOTI-metoclopramide-nasal-spray-104672345100289<\/a><br \/>Follow\u00a0Evoke Pharma\u00a0on Facebook:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WN_spN1sJP5n-euSyASqk-WHmOarvdVLNDBGFkqkDnGMzQoJVLIBFsdvStfpXOHKS_QgYSDIrBFGtIMbWvIJUoUsEBgUhDr1qP_fZBBvo5WxQfaLHDyR1h3ecpMIeN0M-uyVu1B9d0yKkzfjWVbnO2X6v625VZWhjFchB5CYFRXi-zF9fzrSX8xu-oo7o7--3Oecgx8oPpFQsZrB2GsvHZMwnVVaWa8v_t_8rD-2aYvf6Vc5XLSuaSZk8XvLoPR4pKkTY4gHLFTmZ1TSBa5mydjVMNpUKQoBNNfpS9jjT1vbuDI7oYzFwiU3SLVMH4ozZz58DJ-2L4BxCWGEYJu2wh0DchzRaepN0hoj2xSGdQKz0CyP0ic2TrjxjEOANvKGOqAs8DHd8VfrzlfQEufTTy-47z40iC1eIefbTcPpl1FY7XlA-8JRQnc5bgZJ3mqGlMge_zJox6VDCLMmFTftINKgNc_gLCqQ1DZhjO-PC-qofKmiUndgy014QCvI-QS6VUtc-2vQkpvytkYILM57IYCF-B1UR7Baym4Cw3fU6C5R3EBVMkpNKvqISxW4zFjcx2gNLloopdNTIs7O71_yq_l2W3mQebDd6L43znwQ9X2fepu2vCoOLQsT9MIYbB4a6ENN_V8GzlC11Gimn4a8-wrhJkJxtO9-YC63KiFRRx3UN535k-QXQt6ebDIANXvQrF3wYfCjZA6uQj0eeOnF3hyyvGfk-HJpIb6sne8eegefEGbMNdsgvMVaNglsCHuFpY8hN9CGUk_Wu-f_WXXT-ffhcFZpZTerWjkTCXkbgolKgv7yCzNlpZzUP3R0yYfhVhXiTVBJZ2rAkP68LEg1i2xnagft-sBwSUL1kkfYF8c5dHjRzBcXpKF_1k5hKQTvLETdxyo8Imgewxy7Bc6MilDAKX0M1IhMka0Jma-J0wRru8I5A5Q_CMM_x5KgFc7QGom3Nu0tHiWjBpXSno9h1AVMWTnLK-t_T8Wf-XDcqjxdmhAI0N75MLVEjbRVPxxdW4sS8diodrLLTvWYjnkR-kXq17ycXgbSYNgu474DznnyTTI9qE1bWt_aun7zRUtVQu3GECaTq8O_drWdOM0VNOpOrx2lJaX1tIS0PDdO-cFeQ9l38R8gTFSEEQeiheuOgM-3cj1SBHgtpdPCbm7ffg==\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.facebook.com\/Evoke-Pharma-Inc-131313647029724<\/a><br \/>Follow\u00a0Evoke Pharma\u00a0on LinkedIn:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WN_spN1sJP5n-euSyASqk1RV0XNk86qSFe6AXU_1PNZmfMxhsAipUv-1f-6pyWDWiw4kLkfUjCvT8D6G--WpkJVHDO-6sp2jgpKLECGlhB_oQhUykSqJO4NqRn8L4UxNRvsF1P3YOnNiIhN-XQKAqF4OzYErRuZS_eLYkQ2TVtg0A0YfoFTy9wKcxJkoMFlu807ro3NoFWYNduFAXtpV7uBTuVAWDkW7XL_1Oj0tpHEgevyr4Ddq2QeaPYEWaUbG7-EMXlIkKRxEB4qprCC5HOR37h8JU6woOt4TqK_b1NZFdfkCOdgaPJCB0w61myq6uI3RuDVTMpQSkAgWOsGUQHusIZU1gKAomyGY-ewAJQuEQbgnffa3IdXK4fwUN4RXqLFNAGt9ExsOVoNlPJ7CwxIXLEBxYJ1ua7j-r8fzaEzGWHXOGSLC474a2A2rQRZUSFPQK4xkdpja_T42lUQT4FtJBW7k786OA0mMiZAGY4nCtCU7Cep-FcACjfAeAI9yAYrzFLK7rlhDUaYcFSCwFXhGhYquYCI5FFYMqpMLCTAD17XjCE8rcHcEQexT2cFwnRLvNywhb-Ze6eyYABSzQzaTDsSZ1mQzfq8yhsTshhaMRI5I6tiApDXZ615PPknEhDBpgaOYtEUpSdkNhFQpH05C5gGdQb9CZLg1e-YXkeCnC5pyBrvhTZlwswBfyedxgQv28Fs7qdXMkXAZQDgGIa0ejETOjd6u5ynE1mz9J1Ufa_AiGlVaDJQVkU0G_B0AWa9TpYPiwMwEw1Zo742luqd_Puk7PTkuzX5Nn_7ezpx8-N5iwm5Q4vNv2cka-O-Iak_GxOtf0no-4gkqfDZX21LJalUpx2iKflkyAtfbfvadP2Ru5aVzqR5q468OYV4s9Cz5TnZnvoZUtGaWznza6fnpKXbIl35Yz3Ep8YkwTe_i0cACCs9a-ivNvPGgXea5ponFGx5tUJA9cbpKfrI6XbCjQeuMjcpTkuo3Ol4Knbfd4RkX0ny8ogIQfqyUrDygLpmrjB_TCtbuYXBdEqXhCQ==\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.linkedin.com\/company\/evoke-pharma\/<\/a><\/p>\n<p>\n        <strong>About Gimoti<\/strong>\u00ae<strong> (metoclopramide) nasal spray<\/strong><br \/>GIMOTI is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.<\/p>\n<p>\n        <strong>Important Safety Information<\/strong><br \/>\n        <br \/>WARNING: TARDIVE DYSKINESIA<\/p>\n<ul type=\"disc\">\n<li>Metoclopramide can cause tardive dyskinesia (TD), a serious movement disorder that is often irreversible. The risk of developing TD increases with duration of treatment and total cumulative dosage.<\/li>\n<li>Discontinue GIMOTI in patients who develop signs or symptoms of TD. In some patients, symptoms may lessen or resolve after metoclopramide is stopped.<\/li>\n<li>Avoid treatment with metoclopramide (all dosage forms and routes of administration) for longer than 12 weeks because of the increased risk of developing TD with longer-term use<em>.<\/em><\/li>\n<\/ul>\n<p>GIMOTI is not recommended for use in:<\/p>\n<ul type=\"disc\">\n<li>Pediatric patients due to the risk of developing tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates<em>.<\/em><\/li>\n<li>Moderate or severe hepatic impairment (Child-Pugh B or C), moderate or severe renal impairment (creatinine clearance less than 60 mL\/minute), and patients concurrently using strong CYP2D6 inhibitors due to the risk of increased drug exposure and adverse reactions.<\/li>\n<\/ul>\n<p>GIMOTI is contraindicated:<\/p>\n<ul type=\"disc\">\n<li>In patients with a history of tardive dyskinesia (TD) or a dystonic reaction to metoclopramide.<\/li>\n<li>When stimulation of gastrointestinal motility might be dangerous (e.g., in the presence of gastrointestinal hemorrhage, mechanical obstruction, or perforation).<\/li>\n<li>In patients with pheochromocytoma or other catecholamine-releasing paragangliomas. Metoclopramide may cause a hypertensive\/pheochromocytoma crisis, probably due to release of catecholamines from the tumor.<\/li>\n<li>In patients with epilepsy. Metoclopramide may increase the frequency and severity of seizures.<\/li>\n<li>In patients with hypersensitivity to metoclopramide. Reactions have included laryngeal and glossal angioedema and bronchospasm.<\/li>\n<\/ul>\n<p>Potential adverse reactions associated with metoclopramide include Tardive dyskinesia (TD), other extrapyramidal effects (EPS), parkinsonism symptoms, motor restlessness, neuroleptic malignant syndrome (NMS), depression, suicidal ideation and suicide, hypertension, fluid retention, hyperprolactinemia, effects on the ability to drive and operate machinery. Most common adverse reactions (\u22655%) for GIMOTI are: dysgeusia, headache, and fatigue.\u00a0These are not all of the possible side effects of GIMOTI. Call your doctor for medical advice about whether you should take GIMOTI and the possible risk factors and side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rUpXuEVhKw1IS1QFRNOPVGyVQxQKXU_5cktpsdOtZcO0dq9Xf43zSpwTqPznb8cuJOEofKF4RQheETaQNdZHuSylii9jbu3yBIlPFAkgjGOtKkrj0siB23x1aOy1bQ1C\" rel=\"nofollow noopener\" target=\"_blank\">www.fda.gov\/medwatch\u00a0or call 1-800-FDA-1088<\/a>.<\/p>\n<p>\n        <strong>Safe Harbor Statement<\/strong><br \/>\n        <br \/>Evoke cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201ccould,\u201d \u201cintend,\u201d \u201ctarget,\u201d \u201cproject,\u201d \u201ccontemplates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cpotential\u201d or \u201ccontinue\u201d or the negatives of these terms or other similar expressions. These statements are based on the company\u2019s current beliefs and expectations. These forward-looking statements include statements regarding: the anticipated scope and term of any patent protection for GIMOTI; and Evoke\u2019s belief in the strength of the GIMOTI patent protection and ability to defend its intellectual property rights. The inclusion of forward-looking statements should not be regarded as a representation by Evoke that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Evoke\u2019s business, including, without limitation: Evoke\u2019s ability to obtain, maintain and successfully enforce intellectual property protection for Gimoti; Evoke\u2019s ability to obtain additional financing as needed to support its operations; Evoke is entirely dependent on the success of Gimoti;; and other risks and uncertainties detailed in Evoke\u2019s prior press releases and in the periodic reports it files with the\u00a0Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Evoke undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.<\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Daniel Kontoh-Boateng<br \/>DKB Partners<br \/>Tel: 862-213-1398<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=El7YuoWeIQ8NzNaxSYZpNiE6tikF6yxHOGQHuGJt6yNy2IfG5mwr0eE3iPLEgzpvUDWsXupme1hWF2FOjDTUClG-6IirzRImElMfbpZsJvDuC8H4xF4x5JcN1Ly-wWYP-ohqsPv18swf9DYOlWmnhJ_52OBH3cEY2JswQT29IPd2qDLUfZ5HWpCySwhiU2ebnFCadz9TNngHmeonLB2ZYKaAZ4t1wLjEntziErlMVrOETWlc6y75_wI2tpj1g5ypfuYQ9Ldft3q86E5BBV_KKw==\" rel=\"nofollow noopener\" target=\"_blank\">dboateng@dkbpartners.net<\/a>\u00a0\u00a0<\/p>\n<p>\u00a0<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczODU3OSM1MzgwMjAzIzIwMjc2OTE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MmU0OWQ2N2MtNGFiZC00N2JiLWI0ZTEtMTc2OGE2ZjllNWM4LTEwMzgyNTM=\/tiny\/Evoke-Pharma-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Stipulation of Dismissal of Claims, Defenses and Counterclaims for Patent Infringement Case Filed SOLANA BEACH, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) &#8212; Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI\u00ae (metoclopramide) nasal spray, today announced that a joint stipulation of dismissal has been filed in the GIMOTI\u00ae patent infringement case (Civil Action No. 1:22-cv-02019) in\u00a0the United States\u00a0District Court for the District of New Jersey. The filing of the stipulation arises from Teva Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc.\u2019s (\u201cTeva\u201d) conversion from a Paragraph IV certification to a Paragraph III certification.\u00a0\u00a0 A paragraph III Abbreviated New Drug Application (ANDA) is not eligible for approval until the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/evoke-announces-teva-ends-pursuit-of-paragraph-iv-anda-against-gimoti\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Evoke Announces Teva Ends Pursuit of Paragraph IV ANDA Against Gimoti&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-726710","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Evoke Announces Teva Ends Pursuit of Paragraph IV ANDA Against Gimoti - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/evoke-announces-teva-ends-pursuit-of-paragraph-iv-anda-against-gimoti\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Evoke Announces Teva Ends Pursuit of Paragraph IV ANDA Against Gimoti - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Stipulation of Dismissal of Claims, Defenses and Counterclaims for Patent Infringement Case Filed SOLANA BEACH, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) &#8212; Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI\u00ae (metoclopramide) nasal spray, today announced that a joint stipulation of dismissal has been filed in the GIMOTI\u00ae patent infringement case (Civil Action No. 1:22-cv-02019) in\u00a0the United States\u00a0District Court for the District of New Jersey. The filing of the stipulation arises from Teva Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc.\u2019s (\u201cTeva\u201d) conversion from a Paragraph IV certification to a Paragraph III certification.\u00a0\u00a0 A paragraph III Abbreviated New Drug Application (ANDA) is not eligible for approval until the &hellip; Continue reading &quot;Evoke Announces Teva Ends Pursuit of Paragraph IV ANDA Against Gimoti&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/evoke-announces-teva-ends-pursuit-of-paragraph-iv-anda-against-gimoti\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-30T12:06:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczODU3OSM1MzgwMjAzIzIwMjc2OTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evoke-announces-teva-ends-pursuit-of-paragraph-iv-anda-against-gimoti\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evoke-announces-teva-ends-pursuit-of-paragraph-iv-anda-against-gimoti\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Evoke Announces Teva Ends Pursuit of Paragraph IV ANDA Against Gimoti\",\"datePublished\":\"2023-01-30T12:06:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evoke-announces-teva-ends-pursuit-of-paragraph-iv-anda-against-gimoti\\\/\"},\"wordCount\":1097,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evoke-announces-teva-ends-pursuit-of-paragraph-iv-anda-against-gimoti\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczODU3OSM1MzgwMjAzIzIwMjc2OTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evoke-announces-teva-ends-pursuit-of-paragraph-iv-anda-against-gimoti\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evoke-announces-teva-ends-pursuit-of-paragraph-iv-anda-against-gimoti\\\/\",\"name\":\"Evoke Announces Teva Ends Pursuit of Paragraph IV ANDA Against Gimoti - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evoke-announces-teva-ends-pursuit-of-paragraph-iv-anda-against-gimoti\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evoke-announces-teva-ends-pursuit-of-paragraph-iv-anda-against-gimoti\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczODU3OSM1MzgwMjAzIzIwMjc2OTE=\",\"datePublished\":\"2023-01-30T12:06:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evoke-announces-teva-ends-pursuit-of-paragraph-iv-anda-against-gimoti\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evoke-announces-teva-ends-pursuit-of-paragraph-iv-anda-against-gimoti\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evoke-announces-teva-ends-pursuit-of-paragraph-iv-anda-against-gimoti\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczODU3OSM1MzgwMjAzIzIwMjc2OTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczODU3OSM1MzgwMjAzIzIwMjc2OTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evoke-announces-teva-ends-pursuit-of-paragraph-iv-anda-against-gimoti\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Evoke Announces Teva Ends Pursuit of Paragraph IV ANDA Against Gimoti\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Evoke Announces Teva Ends Pursuit of Paragraph IV ANDA Against Gimoti - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/evoke-announces-teva-ends-pursuit-of-paragraph-iv-anda-against-gimoti\/","og_locale":"en_US","og_type":"article","og_title":"Evoke Announces Teva Ends Pursuit of Paragraph IV ANDA Against Gimoti - Market Newsdesk","og_description":"Stipulation of Dismissal of Claims, Defenses and Counterclaims for Patent Infringement Case Filed SOLANA BEACH, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) &#8212; Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI\u00ae (metoclopramide) nasal spray, today announced that a joint stipulation of dismissal has been filed in the GIMOTI\u00ae patent infringement case (Civil Action No. 1:22-cv-02019) in\u00a0the United States\u00a0District Court for the District of New Jersey. The filing of the stipulation arises from Teva Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc.\u2019s (\u201cTeva\u201d) conversion from a Paragraph IV certification to a Paragraph III certification.\u00a0\u00a0 A paragraph III Abbreviated New Drug Application (ANDA) is not eligible for approval until the &hellip; Continue reading \"Evoke Announces Teva Ends Pursuit of Paragraph IV ANDA Against Gimoti\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/evoke-announces-teva-ends-pursuit-of-paragraph-iv-anda-against-gimoti\/","og_site_name":"Market Newsdesk","article_published_time":"2023-01-30T12:06:15+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczODU3OSM1MzgwMjAzIzIwMjc2OTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evoke-announces-teva-ends-pursuit-of-paragraph-iv-anda-against-gimoti\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evoke-announces-teva-ends-pursuit-of-paragraph-iv-anda-against-gimoti\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Evoke Announces Teva Ends Pursuit of Paragraph IV ANDA Against Gimoti","datePublished":"2023-01-30T12:06:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evoke-announces-teva-ends-pursuit-of-paragraph-iv-anda-against-gimoti\/"},"wordCount":1097,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evoke-announces-teva-ends-pursuit-of-paragraph-iv-anda-against-gimoti\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczODU3OSM1MzgwMjAzIzIwMjc2OTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evoke-announces-teva-ends-pursuit-of-paragraph-iv-anda-against-gimoti\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/evoke-announces-teva-ends-pursuit-of-paragraph-iv-anda-against-gimoti\/","name":"Evoke Announces Teva Ends Pursuit of Paragraph IV ANDA Against Gimoti - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evoke-announces-teva-ends-pursuit-of-paragraph-iv-anda-against-gimoti\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evoke-announces-teva-ends-pursuit-of-paragraph-iv-anda-against-gimoti\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczODU3OSM1MzgwMjAzIzIwMjc2OTE=","datePublished":"2023-01-30T12:06:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evoke-announces-teva-ends-pursuit-of-paragraph-iv-anda-against-gimoti\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/evoke-announces-teva-ends-pursuit-of-paragraph-iv-anda-against-gimoti\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evoke-announces-teva-ends-pursuit-of-paragraph-iv-anda-against-gimoti\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczODU3OSM1MzgwMjAzIzIwMjc2OTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczODU3OSM1MzgwMjAzIzIwMjc2OTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evoke-announces-teva-ends-pursuit-of-paragraph-iv-anda-against-gimoti\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Evoke Announces Teva Ends Pursuit of Paragraph IV ANDA Against Gimoti"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/726710","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=726710"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/726710\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=726710"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=726710"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=726710"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}